Live feed
·
INSIDERFilingvia Quantisnow
Inhibikase Therapeutics Inc. logo

Inhibikase Therapeutics (IKT) director Berman received 68,968 Stock Option (Right to Buy)

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Dennis N Berman (director at Inhibikase Therapeutics Inc., IKT) reported that they received 68,968 Stock Option (Right to Buy) on Jan 21, 2025.

Reporting person
Berman Dennis N

Options and other derivatives

Options and other derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Jan 21, 2025Grant or award (A)Stock Option (Right to Buy)On 68,968 Common Stock1, 2, 3, ...+68,968--30,000 direct

Holdings before and after

  • Stock Option (Right to Buy): 0 to 30,000 direct

Footnotes from the filing

  1. 1. The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.
  2. 2. The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.
  3. 3. The transactions reported herein reflect an option repricing (the Repricing ) effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
  4. 4. This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Transaction codes in this filing

Grant or award:
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ

What did Berman report in this IKT Form 4?

Dennis N Berman (director at Inhibikase Therapeutics Inc., IKT) reported that they received 68,968 Stock Option (Right to Buy) on Jan 21, 2025.

What does transaction code A mean on an SEC Form 4?

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

Historical context for IKT

Earlier insider filings at IKT

Quantisnow market dataNASDAQ
Inhibikase Therapeutics Inc. logo
IKT
Inhibikase Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Listed since
2020
Get push alerts for IKT

Follow IKT and get a push notification the moment its next story breaks.

Full IKT profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IKT (Inhibikase Therapeutics Inc.) and more on Quantisnow.